Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diamyd (Diamyd Medical)
- Development stage
- Unknown
- Lead developer
- Diamyd Medical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intralymphatic, Subcutaneous
01
Overview
Diamyd (GAD-alum) is an antigen-specific immunotherapy developed by Diamyd Medical in collaboration with Linköping University for the treatment of Type 1 diabetes mellitus (T1D). It consists of recombinant human glutamic acid decarboxylase 65 (rhGAD65) formulated with aluminum hydroxide (alum) as an adjuvant. The drug is designed to induce immune tolerance to GAD65, a major autoantigen targeted by autoreactive T lymphocytes in pancreatic beta cells. By modulating the immune response, Diamyd aims to preserve endogenous insulin production and prevent further beta-cell destruction. Clinical development has focused on intralymphatic administration, which has shown significant efficacy in maintaining C-peptide levels and improving glycemic control in a specific subgroup of patients carrying the human leukocyte antigen (HLA) DR3-DQ2 haplotype.
- Brand names
- Diamyd
- Other names
- recombinant human glutamic acid decarboxylase 65 formulated with aluminum hydroxideGAD65-alumGAD-65-alumGAD 65-alum
02
Targets
Glutamate decarboxylase 65-specific T-cell receptorGAD65-BCR/Ab (Glutamate decarboxylase 65-specific B-cell receptor and antibodies)
Beyond the preview
Go deeper on Diamyd (Diamyd Medical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diamyd (Diamyd Medical).